ArticleBMC infectious diseases2025
Analysis of factors influencing plasma concentrations of anti-TB drugs in pediatric TB patients.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Guiding point-of-care therapeutic drug monitoring through structure-toxicity principles.Chemical science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe first-line anti-tuberculosis (anti-TB) drugs require long-term administration, and their plasma concentrations are closely associated with therapeutic efficacy and safety. The primary objective of this study was to analyze interindividual and interdrug variability in plasma concentrations of first-line anti-TB drugs in pediatric patients and to investigate factors influencing drug concentrations.
methodsA retrospective analysis was conducted on 110 pediatric tuberculosis (TB) patients who underwent therapeutic drug monitoring (TDM) for anti-TB drugs between January 2022 and November 2023. Patients with complete TDM data were included, defined as those receiving the tablet formulation at doses consistent with the 2010 World Health Organization recommendations, with blood samples collected 5–7 days after drug administration. Accordingly, TDM data were analyzed for isoniazid (INH, n = 105), rifampicin (RFP, n = 83), and pyrazinamide (PZA, n = 103).
resultsTwo hours after administration, the proportions of children with plasma concentrations below the target range were 31.4% (33/105) for INH, 30.1% (25/83) for RFP, and 3.9% (4/103) for PZA. Multivariate logistic regression analysis revealed that higher doses (mg/kg) were significantly associated with achieving a therapeutic plasma concentration (P < 0.05).
conclusionSubtherapeutic plasma concentrations of RFP and INH are common in pediatric TB patients receiving guideline-recommended doses of first-line anti-tuberculosis drugs. The administered dose (mg/kg) significantly influences plasma drug concentrations, underscoring the necessity of TDM for first-line anti-tuberculosis drugs in children and individualized treatment plan adjustments to optimize TB management. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.